This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Carmot Therapeutics, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Daniel Erlanson: Pioneering Modulators for G-Protein Coupled Receptors
Introduction
Daniel Erlanson is an esteemed inventor based in San Francisco, California, known for his significant contributions to the field of pharmaceuticals. With a focus on advancing therapeutic techniques, Erlanson has garnered recognition for his innovative approach to modulating crucial receptors in the human body.
Latest Patents
Erlanson holds a patent for "Modulators of G-protein coupled receptors," which highlights his groundbreaking work with chemical entities capable of modulating the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR). This patent outlines how these chemical entities can agonize, partially agonize, or antagonize these receptors, providing potential treatments for various diseases and disorders. The modulation of GLP-1R and GIPR is particularly beneficial for enhancing existing receptor activities and improving patient outcomes.
Career Highlights
Currently, Daniel Erlanson is affiliated with Carmot Therapeutics, Inc., where he continues to develop innovative solutions in drug modulation. His expertise in pharmaceuticals and receptor modulation positions him as a leader in the field, pushing the boundaries of what's possible in therapeutic interventions.
Collaborations
Throughout his career, Erlanson has collaborated with other notable individuals in the industry, including Raymond V. Fucini and Stig Hansen. These partnerships enhance the depth of research and development at Carmot Therapeutics, fostering a team-oriented environment dedicated to innovation and excellence in therapeutic advancements.
Conclusion
Daniel Erlanson's innovative work in the field of G-protein coupled receptors demonstrates his commitment to improving health outcomes through scientific exploration. With his patent on modulators of GLP-1R and GIPR, he paves the way for future advancements that may significantly alter the landscape of treatment for various conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile